Director at enVVeno Medical (NVNO) sells 140 shares under Rule 10b5-1 plan

Rhea-AI Filing Summary

enVVeno Medical Corp director Francis Duhay reported an open-market sale of 140 shares of Common Stock at a weighted-average price of $11.5224 per share. The sale was completed under a pre-arranged Rule 10b5-1 trading plan adopted in June 2025. Following this transaction, Duhay directly holds 2,502 shares of enVVeno Medical common stock.

Insider Trade Summary 10b5-1

Net Seller: 140 shares ($1,613)

Net Sell 1 txn

Insider Duhay Francis

Role Director

Sold 140 shs ($2K)

Type	Security	Shares	Price	Value
Sale	Common Stock	140	$11.5224	$2K

Holdings After Transaction: Common Stock — 2,502 shares (Direct)

Footnotes (1)

1. This transaction was completed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2025. This transaction was executed in multiple trades during the day at prices ranging from $11.5200 to $11.5450, inclusive. The weighted-average price is reported above. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were completed.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Duhay Francis

(Last) (First) (Middle)

C/O ENVVENO MEDICAL CORPORATION,

70 DOPPLER

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
enVVeno Medical Corp [ NVNO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		S(1)		140	D	$11.5224(2)	2,502	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was completed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2025.

2. This transaction was executed in multiple trades during the day at prices ranging from $11.5200 to $11.5450, inclusive. The weighted-average price is reported above. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were completed.

	/s/ Francis Duhay	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did enVVeno Medical (NVNO) director Francis Duhay report in this Form 4?

Director Francis Duhay reported selling 140 shares of enVVeno Medical common stock. The open-market sale occurred at a weighted-average price of $11.5224 per share, and the transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted in June 2025.

How many enVVeno Medical (NVNO) shares did Francis Duhay sell and at what price?

Francis Duhay sold 140 shares of enVVeno Medical common stock. The trades were executed in multiple transactions between $11.5200 and $11.5450 per share, with a reported weighted-average sale price of $11.5224 per share for the Form 4 disclosure.

How many enVVeno Medical (NVNO) shares does Francis Duhay hold after this sale?

After selling 140 shares, Francis Duhay directly holds 2,502 shares of enVVeno Medical common stock. This post-transaction ownership figure is reported in the Form 4 and reflects his remaining direct holdings following the disclosed open-market sale.

Was the enVVeno Medical (NVNO) share sale by Francis Duhay under a Rule 10b5-1 plan?

Yes. The Form 4 states the transaction was completed under a Rule 10b5-1 trading plan adopted by Francis Duhay in June 2025. Such plans allow pre-scheduled trades, helping separate routine portfolio management from discretionary timing decisions.

What trading range is disclosed for Francis Duhay’s enVVeno Medical (NVNO) sale?

The sale was executed in multiple trades during the day at prices ranging from $11.5200 to $11.5450 per share. The Form 4 reports a weighted-average sale price of $11.5224 per share for the 140 shares sold.